The COVID-19 disease, which is caused by the coronavirus, SARS-COV2 had affected the world in 2020 causing a high mortality and morbidity in affected patients. Numerous clinical studies performed worldwide have demonstrated the great potential of MSCs used to prevent complications caused by COVID. In this review, we focus on the potency of mesenchymal stem cell (MSCs) for treating critically ill patients at the risk of developing permanent lung damage and discussed the aspects of this proposed treatment using reported clinical trials and hypotheses.